Daily GLP-1 receptor agonist. Brand names: Victoza (T2D), Saxenda (chronic weight management). Older agent, lower weight loss than semaglutide or tirzepatide.
Daily GLP-1 receptor agonist. Brand names: Victoza (T2D), Saxenda (chronic weight management). Older agent, lower weight loss than semaglutide or tirzepatide.
Liraglutide is sold by Novo Nordisk as Victoza for type 2 diabetes and as Saxenda for chronic weight management. Both are FDA-approved daily GLP-1 receptor agonists, so the brand prescribed depends on whether the goal is glucose control or weight management.
Liraglutide is dosed daily and produces less weight loss than semaglutide or tirzepatide. For comparison, semaglutide 2.4 mg averaged −14.9% at 68 weeks in STEP 1, and tirzepatide 15 mg averaged −20.9% at 72 weeks in SURMOUNT-1 (treatment-regimen estimand).
Read October 14, 2026: Wegovy pen $349 a month via NovoCare (new patients $199 for the first two fills through Dec 31, 2026) and Zepbound from $299 a month at 2.5 mg via LillyDirect. Compounded semaglutide at NexLife is $119 a month on a 12-month plan charged monthly, but is not FDA-approved.